BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30185662)

  • 21. HPV positive oropharyngeal cancer and treatment deintensification: how pertinent is it?
    Laskar SG; Swain M
    J Cancer Res Ther; 2015; 11(1):6-9. PubMed ID: 25879328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oropharyngeal cancer - is it time to change management according to human papilloma virus status?
    Mehanna H; Olaleye O; Licitra L
    Curr Opin Otolaryngol Head Neck Surg; 2012 Apr; 20(2):120-4. PubMed ID: 22327790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer.
    Dahlstrom KR; Li G; Hussey CS; Vo JT; Wei Q; Zhao C; Sturgis EM
    Cancer; 2015 Oct; 121(19):3455-64. PubMed ID: 26094818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [OROPHARYNGEAL CANCER: THE VIRUS THAT CHANGED THE RULES].
    Feibish N; Bartal K; Doweck I
    Harefuah; 2020 Feb; 159(1):137-141. PubMed ID: 32048496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer.
    Guo T; Qualliotine JR; Ha PK; Califano JA; Kim Y; Saunders JR; Blanco RG; D'Souza G; Zhang Z; Chung CH; Kiess A; Gourin CG; Koch W; Richmon JD; Agrawal N; Eisele DW; Fakhry C
    Cancer; 2015 Jun; 121(12):1977-84. PubMed ID: 25782027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using a semi-conductor sequencing-based panel for genotyping of HPV-positive and HPV-negative oropharyngeal cancer: a retrospective pilot study.
    Ham JC; Tops BBJ; Driessen CML; van Raaij AWM; Slootweg PJ; Melchers WJG; Ligtenberg MJL; van Herpen CML
    Clin Otolaryngol; 2017 Jun; 42(3):681-686. PubMed ID: 27882657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes.
    Varier I; Keeley BR; Krupar R; Patsias A; Dong J; Gupta N; Parasher AK; Genden EM; Miles BA; Teng M; Bakst RL; Gupta V; Misiukiewicz KJ; Chiao EY; Scheurer ME; Laban S; Zhang D; Ye F; Cui M; Demicco EG; Posner MR; Sikora AG
    Head Neck; 2016 Sep; 38(9):1330-7. PubMed ID: 27080140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy.
    Ihloff AS; Petersen C; Hoffmann M; Knecht R; Tribius S
    Oral Oncol; 2010 Oct; 46(10):705-11. PubMed ID: 20843732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma.
    Hui AB; Lin A; Xu W; Waldron L; Perez-Ordonez B; Weinreb I; Shi W; Bruce J; Huang SH; O'Sullivan B; Waldron J; Gullane P; Irish JC; Chan K; Liu FF
    Clin Cancer Res; 2013 Apr; 19(8):2154-62. PubMed ID: 23459718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.
    Lang Kuhs KA; Kreimer AR; Trivedi S; Holzinger D; Pawlita M; Pfeiffer RM; Gibson SP; Schmitt NC; Hildesheim A; Waterboer T; Ferris RL
    Cancer; 2017 Nov; 123(22):4382-4390. PubMed ID: 28950407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer.
    Um SH; Mundi N; Yoo J; Palma DA; Fung K; MacNeil D; Wehrli B; Mymryk JS; Barrett JW; Nichols AC
    J Clin Virol; 2014 Sep; 61(1):94-100. PubMed ID: 25027574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sexual health in oral oncology: breaking the news to patients with human papillomavirus-positive oropharyngeal cancer.
    Evans M; Powell NG
    Head Neck; 2014 Nov; 36(11):1529-33. PubMed ID: 24913820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Oropharyngeal Cancer in the HPV Era.
    Naghavi AO; Strom TJ; Ahmed KA; Echevarria MI; Abuodeh YA; Venkat PS; Frakes JM; Harrison LB; Trotti AM; Caudell JJ
    Cancer Control; 2016 Jul; 23(3):197-207. PubMed ID: 27556659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic analysis of oropharyngeal carcinomas reveals novel HPV-associated biological pathways.
    Slebos RJ; Jehmlich N; Brown B; Yin Z; Chung CH; Yarbrough WG; Liebler DC
    Int J Cancer; 2013 Feb; 132(3):568-79. PubMed ID: 22733545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
    Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.
    Huang SH; Perez-Ordonez B; Liu FF; Waldron J; Ringash J; Irish J; Cummings B; Siu LL; Kim J; Weinreb I; Hope A; Gullane P; Brown D; Shi W; O'Sullivan B
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):276-83. PubMed ID: 20950953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.